 |
|
|
| |
Response-guided peginterferon alfa-2a therapy based on HBsAg levels at week 12 and week 24 or 48 improves response rates in HBeAg-negative, genotype D patients
|
| |
| |
Reported by Jules Levin
Presented at The 47th Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, 18-22 April, 2012
P. Lampertico,1 M. Vigano,1 G.G. Di Costanzo,2 E. Sagnelli,3 M. Fasano,4 V. Di Marco,5 S. Boninsegna,6 P. Farci,7 S. Fargion,8 T. Giuberti,9 V. Rothe,10 L. Regep,11 A. Caputo,12 F. Facchetti,1 M. Colombo1 on behalf of the PegBeLiver Study Group 11st Gastroenterology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy; 2Liver Unit, Cardarelli Hospital, Naples, Italy; 3Infectious Disease Unit, SS. Anna and Sebastiano Hospital, Caserta, Italy; 4Clinic of Infectious Diseases, Università di Bari, Bari, Italy; 5Gastroenterology and Hepatology Unit, (Di.Bi.M.I.S.) University of Palermo, Palermo, Italy; 6Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, Italy; 7Medical Science Department, University of Cagliari, Monserrato, Italy;
8UO Internal Medicine 1B-Fondazione IRCCS Ca' Granda Policlinico Hospital, Univerisity of Milan, Italy; 9Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero, University of Parma, Parma, Italy; 10IST GmbH, Mannheim, Germany; 11F. Hoffmann-La Roche, Basel, Switzerland; 12Roche, Monza, Italy
|
| |
|
|
|
|
|
